Celcuity Inc. (NASDAQ:CELC) Given Average Rating of “Buy” by Analysts

Celcuity Inc. (NASDAQ:CELC) has received a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $29.20.

CELC has been the topic of a number of research analyst reports. Craig Hallum reaffirmed a “buy” rating and set a $27.00 price objective (up from $25.00) on shares of Celcuity in a research report on Thursday, May 16th. SVB Leerink initiated coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a research report on Monday, July 22nd. Stifel Nicolaus reiterated a “buy” rating and issued a $40.00 target price on shares of Celcuity in a research note on Thursday, May 16th. Finally, Needham & Company LLC reduced their target price on shares of Celcuity from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Friday, May 31st.

Institutional Trading of Celcuity

A number of institutional investors have recently added to or reduced their stakes in CELC. Perceptive Advisors LLC acquired a new stake in shares of Celcuity in the fourth quarter worth $21,583,000. Baker BROS. Advisors LP lifted its stake in shares of Celcuity by 189.9% in the first quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock worth $33,534,000 after buying an additional 1,017,000 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Celcuity in the first quarter worth $3,545,000. Commodore Capital LP lifted its stake in shares of Celcuity by 3.6% in the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock worth $25,566,000 after buying an additional 60,563 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Celcuity in the second quarter worth $888,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

Shares of CELC opened at $17.95 on Tuesday. The company’s 50 day moving average price is $16.27 and its 200 day moving average price is $16.63. Celcuity has a 52 week low of $8.39 and a 52 week high of $22.19. The company has a market capitalization of $630.05 million, a PE ratio of -6.46 and a beta of 0.81. The company has a debt-to-equity ratio of 0.28, a quick ratio of 11.23 and a current ratio of 11.23.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.07. Research analysts expect that Celcuity will post -2.86 EPS for the current fiscal year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.